Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio, Inc. (NASDAQ: TELA) announced its forthcoming financial results for Q4 and full year 2021, scheduled for release on March 21, 2022. The company specializes in innovative soft-tissue reconstruction solutions that enhance clinical outcomes. A conference call will follow at 4:30 p.m. ET the same day, allowing investors to discuss the financial results. TELA prioritizes the preservation of the patient's anatomy while minimizing reliance on permanent synthetic materials. More details can be found on TELA's investor relations website.
TELA Bio, a medical technology company, has launched the SiteGuard No Rinse Antimicrobial Solution, aimed at preventing surgical site infections in plastic reconstructive surgery. Utilizing proprietary XBIO Technology, it targets bacterial biofilms that resist standard treatments, providing over five hours of protection. Early market feedback has been positive, and TELA aims to expand awareness nationwide. The product aligns with TELA's commitment to innovative soft-tissue solutions that minimize reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced on February 25, 2022, the approval of stock options for 17 newly hired employees, totaling 63,800 shares. The options have an exercise price of $11.75 per share, reflecting the closing price on the grant date. These options are part of the employment agreement and will vest over four years, with 25% vesting after the first year and the rest monthly. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes while preserving patients' anatomy.
TELA Bio reported third quarter 2021 revenue of $7.7 million, a 44% year-over-year increase. Increased demand for OviTex® products contributed to a 34% revenue rise, with OviTex PRS sales soaring 101%.
Despite challenges from COVID-19, the company maintained its full-year revenue guidance of $28.0 million to $30.0 million, reflecting growth of 54% to 65%. Operating expenses rose to $11.8 million, leading to a loss from operations of $7.2 million. Cash reserves stood at $53.6 million as of September 30, 2021.
TELA Bio announced encouraging results from the 12-month follow-up of its BRAVO study, involving 75 patients treated with OviTex Reinforced Tissue Matrix for ventral hernia repair. The data indicates a low hernia recurrence rate of 2.7%, with the final 24-month analysis showing rates below 5%. The study also reported low surgical site occurrences and significant improvements in patient quality of life. The results affirm TELA Bio's commitment to addressing the shortcomings of traditional hernia repair materials.
MALVERN, Pa., Nov. 08, 2021 - TELA Bio, Inc. (NASDAQ: TELA) announced its participation in key healthcare conferences, including the Canaccord Genuity MedTech Forum, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference. Management will present on November 18 and 22, 2021. These events focus on TELA's innovative tissue reinforcement materials aimed at improving outcomes in soft tissue reconstruction. Live webcasts will be accessible for stakeholders.
TELA Bio has entered a distribution agreement with Next Science for the exclusive rights to market Next Science's proprietary antimicrobial surgical wash in the US, leveraging XBIO technology. This no-rinse solution provides over five hours of protection against bacterial biofilms, addressing a critical need in plastic reconstructive surgery. TELA also secured a right of first negotiation for the EU market upon CE approval. This partnership aims to enhance TELA's product offerings and improve infection control in surgical procedures.
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its third quarter 2021 financial results on November 10, 2021, followed by a conference call at 4:30 p.m. ET. The company focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction. Its products aim to improve clinical outcomes while minimizing the use of permanent synthetic materials. Investors can access the conference call by dialing specific numbers or through a webcast available on TELA's investor website.
TELA Bio, Inc. has appointed Roberto Cuca as the new Chief Operating Officer (COO) and Chief Financial Officer (CFO). With over 25 years of experience in the healthcare sector, including leadership roles at OraSure Technologies and Trevana, Cuca's expertise is expected to bolster TELA's operations and financial management. On his appointment date, he was granted an option to purchase 144,000 shares of TELA's common stock, indicating the company's confidence in his capabilities. The move aims to drive growth and enhance TELA’s strategic execution in tissue reinforcement technologies.
TELA Bio recently shared promising clinical results at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons meeting, highlighting advancements in hernia repair solutions.
Key findings include a 2.7% recurrence rate and 1.8% surgical site occurrence rate using the OviTex in robotic-assisted procedures, demonstrating its efficacy as a natural repair alternative.
Further studies indicate a 1.3% recurrence rate across 619 implants with a unique surgical technique, underscoring the potential of OviTex in complex repairs.